Trials / Completed
CompletedNCT00267358
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Helsinn Therapeutics (U.S.), Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC-1291 HCl | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2005-12-20
- Last updated
- 2013-09-02
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00267358. Inclusion in this directory is not an endorsement.